Titlebook: Cardiovascular Biomarkers; Pathophysiology and David A. Morrow Book 2006 Humana Press 2006 cardiovascular.heart.heart disease.myocardial i

懒洋洋

Emerging Biomarkers of Myocardial Ischemiao present to the emergency department with a complaint of chest pain therefore require substantial diagnostic effort to determine whether their symptoms are related to acute myocardial ischemia. Present diagnostic approaches are typically protocol driven and include serial electrocardiograms and bio

向外供接触

epidermis

Analytic Issues for Clinical Use of C-Reactive Proteintrated that slight increases in CRP concentration, within the normal range, can predict future vascular events, thus reflecting the inflammatory component of atherosclerosis. It was necessary to develop new high-sensitivity methods for this clinical application, and to establish cut points for risk

放逐

overrule

窝转脊椎动物

Defining Myocardial Infarctionbased on the following biomarker criteria: Maximal concentration of troponin T or I exceeding the decision limit (99th percentile of the values for a reference control group) manifesting a dynamic pattern on at least one occasion during the first 24 h after the index clinical event; if the value is

阴谋小团体

Cardiac Troponin After Revascularization Proceduresnical significance is less well established. However, clinical studies show that large elevations (more than five times ULN) are associated with worse prognosis. Cardiac troponin is elevated more frequently after PCI and CABG. A number of procedure-related factors contribute to the rises in troponin

Climate

是剥皮

技术

Developing a Marker of Ischemiaong argument toward development of biochemical markers of myocardial ischemia. Nevertheless, there are many challenges to this effort. The physiology is complex, and it is complicated by the issues of chronicity, timing, and severity. The absence of a “gold standard” for diagnosis of unstable angina